QuatRx files for $86.2M IPO

QuatRx Pharmaceuticals of Ann Arbor, MI, has filed for an IPO designed to raise $86.2 million. QuatRx was founded in 2000 and has been developing drugs for cardiovascular, metabolic and endocrine disorders. The underwriters of the offering will be Banc of America Securities, as sole book-running manager, SG Cowen & Co., as co-lead manager, and Lazard Capital Markets and Pacific Growth Equities as co-managers.

- read this release for more information

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.